William Carpenter

Summary

Affiliation: University of Maryland
Country: USA

Publications

  1. doi request reprint Psychotic disorders in DSM-5: Summary of changes
    William T Carpenter
    Department of Psychiatry and Pharmacology, Maryland Psychiatric Research Center, University of Maryland School of Medicine, Baltimore, MD, USA The VISN 5 MIRECC, Veterans Administration, Baltimore, MD, USA Electronic address
    Asian J Psychiatr 6:266-8. 2013
  2. doi request reprint Another view of the history of antipsychotic drug discovery and development
    W T Carpenter
    Department of Psychiatry, Maryland Psychiatric Research Center, University of Maryland School of Medicine, Baltimore, MD, USA
    Mol Psychiatry 17:1168-73. 2012
  3. ncbi request reprint Diazepam treatment of early signs of exacerbation in schizophrenia
    W T Carpenter
    Maryland Psychiatric Research Center, Department of Psychiatry, University of Maryland, Baltimore 21228, USA
    Am J Psychiatry 156:299-303. 1999
  4. ncbi request reprint At issue: A model for academic/industry collaboration
    William T Carpenter
    Department of Psychiatry, University of Maryland School of Medicine, Maryland Psychiatric Research Center, PO Box 21247, Baltimore, MD 21228, USA
    Schizophr Bull 30:997-1004. 2004
  5. pmc Evidence-based therapeutics--introducing the Cochrane corner
    William T Carpenter
    Schizophr Bull 33:633-4. 2007
  6. pmc The evolution of drug development in schizophrenia: past issues and future opportunities
    William T Carpenter
    Department of Psychiatry, Maryland Psychiatric Research Center, University of Maryland School of Medicine, Baltimore, MD 21228, USA
    Neuropsychopharmacology 33:2061-79. 2008
  7. doi request reprint Lessons to take home from CATIE
    William T Carpenter
    Maryland Psychiatric Research Center, Department of Psychiatry, University of Maryland School of Medicine, Baltimore, MD 21228, USA
    Psychiatr Serv 59:523-5. 2008
  8. ncbi request reprint Commentary on the Soteria project: misguided therapeutics
    William T Carpenter
    Maryland Psychiatric Research Center, University of Maryland, School of Medicine, Baltimore 21228, USA
    Schizophr Bull 28:577-81; discussion 583-8. 2002
  9. doi request reprint The psychoses: cluster 3 of the proposed meta-structure for DSM-V and ICD-11
    W T Carpenter
    Maryland Psychiatric Research Center, University of Maryland School of Medicine, Baltimore, MD 21228, USA
    Psychol Med 39:2025-42. 2009
  10. ncbi request reprint Comparative effectiveness of fluphenazine decanoate injections every 2 weeks versus every 6 weeks
    W T Carpenter
    Maryland Psychiatric Research Center and the Department of Psychiatry, University of Maryland School of Medicine, Baltimore 21228, USA
    Am J Psychiatry 156:412-8. 1999

Research Grants

  1. Multidisciplinary Schizophrenia Research Training
    William Carpenter; Fiscal Year: 2007
  2. RESEARCH ETHICS IN SCHIZOPHRENIA
    William Carpenter; Fiscal Year: 2007
  3. RESEARCH ETHICS IN SCHIZOPHRENIA
    William Carpenter; Fiscal Year: 2003
  4. TREATMENT OF NEGATIVE SYMPTOMS & COGNITIVE IMPAIRMENTS
    William Carpenter; Fiscal Year: 2003

Detail Information

Publications48

  1. doi request reprint Psychotic disorders in DSM-5: Summary of changes
    William T Carpenter
    Department of Psychiatry and Pharmacology, Maryland Psychiatric Research Center, University of Maryland School of Medicine, Baltimore, MD, USA The VISN 5 MIRECC, Veterans Administration, Baltimore, MD, USA Electronic address
    Asian J Psychiatr 6:266-8. 2013
    ..The specific nature of these revisions in the DSM-5 criteria for schizophrenia and other psychotic disorders along with their rationale are summarized in this article...
  2. doi request reprint Another view of the history of antipsychotic drug discovery and development
    W T Carpenter
    Department of Psychiatry, Maryland Psychiatric Research Center, University of Maryland School of Medicine, Baltimore, MD, USA
    Mol Psychiatry 17:1168-73. 2012
    ..New clinical and basic neuroscience paradigms may guide the near future and provide a more heuristic construct for novel and innovative discovery...
  3. ncbi request reprint Diazepam treatment of early signs of exacerbation in schizophrenia
    W T Carpenter
    Maryland Psychiatric Research Center, Department of Psychiatry, University of Maryland, Baltimore 21228, USA
    Am J Psychiatry 156:299-303. 1999
    ..This study examined diazepam efficacy for this phase of treatment...
  4. ncbi request reprint At issue: A model for academic/industry collaboration
    William T Carpenter
    Department of Psychiatry, University of Maryland School of Medicine, Maryland Psychiatric Research Center, PO Box 21247, Baltimore, MD 21228, USA
    Schizophr Bull 30:997-1004. 2004
    ..We discuss the principles involved and the resolutions achieved in the hope that it may provide a useful model for addressing academic/industry scientific collaborations...
  5. pmc Evidence-based therapeutics--introducing the Cochrane corner
    William T Carpenter
    Schizophr Bull 33:633-4. 2007
  6. pmc The evolution of drug development in schizophrenia: past issues and future opportunities
    William T Carpenter
    Department of Psychiatry, Maryland Psychiatric Research Center, University of Maryland School of Medicine, Baltimore, MD 21228, USA
    Neuropsychopharmacology 33:2061-79. 2008
    ..Success in drug discovery for cognition and negative symptom pathologies may bring forth issues in ethics as the potential for enhancing normal function is explored...
  7. doi request reprint Lessons to take home from CATIE
    William T Carpenter
    Maryland Psychiatric Research Center, Department of Psychiatry, University of Maryland School of Medicine, Baltimore, MD 21228, USA
    Psychiatr Serv 59:523-5. 2008
    ..Bottom line: the dichotomy between first- and second-generation antipsychotics was not supported by efficacy data (and now, is not supported effectiveness data). Only clozapine has documented superiority in treatment-resistant cases...
  8. ncbi request reprint Commentary on the Soteria project: misguided therapeutics
    William T Carpenter
    Maryland Psychiatric Research Center, University of Maryland, School of Medicine, Baltimore 21228, USA
    Schizophr Bull 28:577-81; discussion 583-8. 2002
  9. doi request reprint The psychoses: cluster 3 of the proposed meta-structure for DSM-V and ICD-11
    W T Carpenter
    Maryland Psychiatric Research Center, University of Maryland School of Medicine, Baltimore, MD 21228, USA
    Psychol Med 39:2025-42. 2009
    ..In an effort to group mental disorders on the basis of etiology, five clusters have been proposed. Here we consider the validity of the cluster comprising selected psychotic and related disorders...
  10. ncbi request reprint Comparative effectiveness of fluphenazine decanoate injections every 2 weeks versus every 6 weeks
    W T Carpenter
    Maryland Psychiatric Research Center and the Department of Psychiatry, University of Maryland School of Medicine, Baltimore 21228, USA
    Am J Psychiatry 156:412-8. 1999
    ..The authors tested a new dose reduction approach: increasing the interval between injections during intramuscular decanoate antipsychotic treatment...
  11. ncbi request reprint Sense and nonsense: an essay on schizophrenia research ethics
    W T Carpenter
    Maryland Psychiatric Research Center, University of Maryland School of Medicine, Baltimore 21228, USA
    Schizophr Res 35:219-25; discussion 227-36. 1999
    ....
  12. ncbi request reprint Decisional capacity for informed consent in schizophrenia research
    W T Carpenter
    Maryland Psychiatric Research Center and the Department of Psychiatry, University of Maryland, Baltimore 21228, USA
    Arch Gen Psychiatry 57:533-8. 2000
    ....
  13. ncbi request reprint From clinical trial to prescription
    William T Carpenter
    Maryland Psychiatric Research Center, PO Box 21247, Baltimore, MD 21228, USA
    Arch Gen Psychiatry 59:282-5. 2002
    ..Most hotly debated is the role of money in the creation and dissemination of knowledge...
  14. ncbi request reprint Commentary: how the doctor can counter commercial bias in the dissemination of pharmacotherapeutic knowledge
    William T Carpenter
    Maryland Psychiatric Research Center, University of Maryland School of Medicine, Baltimore, MD21228, USA
    J Nerv Ment Dis 190:593-6. 2002
  15. ncbi request reprint Clinical constructs and therapeutic discovery
    William T Carpenter
    University of Maryland Baltimore, Maryland Psychiatric Research Center, PO Box 21247, Baltimore, MD 21228, USA
    Schizophr Res 72:69-73. 2004
    ..Antipsychotic drugs fail to address these pathologies. These unmet treatment needs are clinical targets for drug discovery involving novel therapeutic pathways...
  16. ncbi request reprint The relationship of clozapine and haloperidol treatment response to prefrontal, hippocampal, and caudate brain volumes
    Celso Arango
    Maryland Psychiatric Research Center, Department of Psychariatry, University of Maryland, MD 21228, USA
    Am J Psychiatry 160:1421-7. 2003
    ..The study was designed to assess the predictive relationship between brain structure volume and positive and negative symptom response to clozapine and haloperidol...
  17. ncbi request reprint The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments
    Robert W Buchanan
    Maryland Psychiatric Research Center, University of Maryland School of Medicine, Baltimore, MD 21228, USA
    Am J Psychiatry 164:1593-602. 2007
    ..Agents that act at the glycine site of the N-methyl-D-aspartic acid (NMDA) glutamatergic receptor have been suggested as promising treatments for moderate to severe negative symptoms and cognitive impairments...
  18. pmc Identifying unmet therapeutic domains in schizophrenia patients: the early contributions of Wayne Fenton from Chestnut Lodge
    Thomas H McGlashan
    Department of Psychiatry, Yale University, USA
    Schizophr Bull 33:1086-92. 2007
    ..The results have radically changed the paradigm for discovery with emphasis on impaired cognition and negative symptom psychopathology...
  19. pmc Neuropsychology of the deficit syndrome: new data and meta-analysis of findings to date
    Alex S Cohen
    Department of Psychology, University of Maryland, College Park, USA
    Schizophr Bull 33:1201-12. 2007
    ..The question of whether deficit patients exhibit a unique cognitive impairment profile will require a more sophisticated and rigorous examination of the neuropsychology of the deficit syndrome...
  20. ncbi request reprint Adverse effects and laboratory parameters of high-dose olanzapine vs. clozapine in treatment-resistant schizophrenia
    Deanna L Kelly
    Maryland Psychiatric Research Center, University of Maryland, Baltimore, Maryland 21228, USA
    Ann Clin Psychiatry 15:181-6. 2003
    ..High doses of olanzapine during 8 weeks of treatment did not increase lipids and liver enzymes like clozapine did. Olanzapine at 50 mg/day may be associated with more anticholinergic effects and weight gain than clozapine...
  21. ncbi request reprint Olanzapine treatment of residual positive and negative symptoms
    Robert W Buchanan
    Maryland Psychiatric Research Center, Department of Psychiatry, University of Maryland, Baltimore 21228, USA
    Am J Psychiatry 162:124-9. 2005
    ..The authors examined the comparative efficacy and safety of olanzapine and haloperidol in outpatients with partially responsive schizophrenia...
  22. pmc White matter alterations in deficit schizophrenia
    Laura M Rowland
    Department of Psychiatry, Maryland Psychiatric Research Center, University of Maryland School of Medicine, P O Box 21247, Baltimore, MD 21228, USA
    Neuropsychopharmacology 34:1514-22. 2009
    ..These findings provide further support for altered frontal-parietal network in deficit schizophrenia...
  23. ncbi request reprint Correlations between rCBF and symptoms in two independent cohorts of drug-free patients with schizophrenia
    Adrienne C Lahti
    Maryland Psychiatric Research Center, University of Maryland School of Medicine, Baltimore, MD 21228, USA
    Neuropsychopharmacology 31:221-30. 2006
    ..The involvement of both frontal and parietal regions is implicated in the pathophysiology of negative symptoms...
  24. ncbi request reprint The Declaration of Helsinki and clinical trials: a focus on placebo-controlled trials in schizophrenia
    William T Carpenter
    Maryland Psychiatric Research Center, Univeristy of Maryland School of Medicine, USA
    Am J Psychiatry 160:356-62. 2003
    ..The authors' goal was to consider ethical approaches to placebo-controlled clinical trials in the light of the evolving Declaration of Helsinki, with special attention to applications to research on schizophrenia...
  25. ncbi request reprint First-episode schizophrenia: a focus on pharmacological treatment and safety considerations
    Deanna L Kelly
    Maryland Psychiatric Research Center, Department of Psychiatry, University of Maryland School of Medicine, Baltimore, Maryland 21228, USA
    Drugs 65:1113-38. 2005
    ....
  26. ncbi request reprint Dihydropyrimidinase-related protein 2 (DRP-2) gene and association to deficit and nondeficit schizophrenia
    L Elliot Hong
    Department of Psychiatry, Maryland Psychiatric Research Center, School of Medicine, University of Maryland, Baltimore, 21228, USA
    Am J Med Genet B Neuropsychiatr Genet 136:8-11. 2005
    ..2%, P =0.050) forms of schizophrenia compared to controls (allele frequency 25.0%). We conclude that the DRP-2 *2236 C allele may mark another polymorphism in DRP-2, or in a nearby gene, that may influence susceptibility to schizophrenia...
  27. ncbi request reprint Optimistic bias in the perception of personal risk: patterns in schizophrenia
    Kristen J Prentice
    Maryland Psychiatric Research Center, P O Box 21247, Baltimore, MD 21228, USA
    Am J Psychiatry 162:507-12. 2005
    ..The authors investigated whether schizophrenia patients share the same optimistic biases frequently demonstrated by non-ill adults in their perceptions of personal risk...
  28. ncbi request reprint Summer birth and deficit schizophrenia: a pooled analysis from 6 countries
    Erick Messias
    Department of Psychiatry, School of Medicine, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, USA
    Arch Gen Psychiatry 61:985-9. 2004
    ..In some reports, summer birth has been associated with deficit schizophrenia. Deficit schizophrenia and nondeficit schizophrenia also differ in several other ways...
  29. ncbi request reprint Remission in schizophrenia: proposed criteria and rationale for consensus
    Nancy C Andreasen
    Department of Psychiatry, University of Iowa, Iowa City, Iowa, USA
    Am J Psychiatry 162:441-9. 2005
    ..These criteria should facilitate research and support a positive, longer-term approach to studying outcome in patients with schizophrenia...
  30. pmc Feasibility of reducing the duration of placebo-controlled trials in schizophrenia research
    Robert P McMahon
    Maryland Psychiatric Research Center, Department of Psychiatry, University of Maryland Baltimore Medical School, Baltimore, MD, USA
    Schizophr Bull 34:292-301. 2008
    ..Shortening placebo-controlled trials would reduce patient burden and ethical objections to prolonged administration of placebo and reduce potential bias due to high dropout rates in longer clinical trials...
  31. ncbi request reprint Maintaining informed consent validity during lengthy research protocols
    Kristen J Prentice
    University of Maryland School of Medicine, USA
    IRB 29:1-6. 2007
  32. pmc Will the Kraepelinian dichotomy survive DSM-V?
    Bernard A Fischer
    Department of Psychiatry, Maryland Psychiatric Research Center, VA Capitol Health Care Network VISN 5 MIRECC and University of Maryland School of Medicine, Baltimore, MD 21228, USA
    Neuropsychopharmacology 34:2081-7. 2009
    ..An alternative paradigm based on domains of pathology is more powerful for studies of etiology, pathophysiology, and therapeutic discovery...
  33. ncbi request reprint Neuroplasticity and schizophrenia
    Douglas O Frost
    Department of Pharmacology and Experimental Therapeutics, Baltimore, Maryland, USA
    Biol Psychiatry 56:540-3. 2004
    ..Although the focus of this workshop was schizophrenia, the phenomena considered are pertinent to other disorders, such as depression and drug abuse...
  34. ncbi request reprint The costs of drugs for schizophrenia
    Robert Freedman
    Am J Psychiatry 163:2029-31. 2006
  35. ncbi request reprint Another view of therapy for cognition in schizophrenia
    William T Carpenter
    Biol Psychiatry 51:969-71. 2002
  36. pmc The NIMH-MATRICS consensus statement on negative symptoms
    Brian Kirkpatrick
    Department of Psychiatry and Health Behavior, Medical College of Georgia, USA
    Schizophr Bull 32:214-9. 2006
  37. ncbi request reprint Clarifying standards for using placebos
    Robert J Levine
    Science 300:1659-61. 2003
  38. pmc Treatment of schizophrenia negative symptoms: future prospects
    Stephen M Erhart
    UCLA Department of Psychiatry and Biobehavioral Sciences, USA
    Schizophr Bull 32:234-7. 2006
    ..We review the continuing limitations in treatment and discuss possible sources of heterogeneity among negative symptoms. We also anticipate conceptual uncertainties that may arise with forthcoming treatment developments...
  39. ncbi request reprint Targeting schizophrenia research to patient outcomes
    William T Carpenter
    Am J Psychiatry 163:353-5. 2006
  40. ncbi request reprint Challenge to atypical antipsychotic drug effect on cognition
    William T Carpenter
    Am J Psychiatry 164:1910-1; author reply 1911-2. 2007
  41. ncbi request reprint The efficacy of high-dose olanzapine versus clozapine in treatment-resistant schizophrenia: a double-blind crossover study
    Robert R Conley
    J Clin Psychopharmacol 23:668-71. 2003
  42. ncbi request reprint The deficit syndrome in schizophrenia: implications for the treatment of negative symptoms
    Celso Arango
    Servicio de Psiquiatria, Hospital General Gregorio Maranon, C Ibiza 43, 280079 Madrid, Spain
    Eur Psychiatry 19:21-6. 2004
    ..The loss of precious human experiences and the association with poor long-term functional outcome justifies a focused and dedicated effort to discover the causes and treatments of this distinctive aspect of schizophrenia...
  43. ncbi request reprint First- and second-generation antipsychotics: learning from CUtLASS and CATIE
    Rajiv Tandon
    Arch Gen Psychiatry 64:977-8; author reply 979-80. 2007
  44. ncbi request reprint The schizophrenia paradigm: a hundred-year challenge
    William T Carpenter
    J Nerv Ment Dis 194:639-43. 2006
  45. pmc Traditional ethics and new sensitivities
    William T Carpenter
    Schizophr Bull 32:1-2. 2006
  46. ncbi request reprint Association between polymorphism of the SNAP29 gene promoter region and schizophrenia
    Ikwunga Wonodi
    Schizophr Res 78:339-41. 2005
  47. ncbi request reprint Schizophrenia: disease, syndrome, or dimensions?
    William T Carpenter
    Fam Process 46:199-206. 2007
    ..This view has been challenged by a series of studies during the past three decades. These investigations are summarized in this report. Implications for clinical work with families are considered...
  48. ncbi request reprint Was Joan of Arc criminally, responsible for her acts alleged of heresy?
    Karen Sullivan
    Bard College, Annandale on Hudson, New York, USA
    Pharos Alpha Omega Alpha Honor Med Soc 67:4-11. 2004

Research Grants18

  1. Multidisciplinary Schizophrenia Research Training
    William Carpenter; Fiscal Year: 2007
    ..abstract_text> ..
  2. RESEARCH ETHICS IN SCHIZOPHRENIA
    William Carpenter; Fiscal Year: 2007
    ....
  3. RESEARCH ETHICS IN SCHIZOPHRENIA
    William Carpenter; Fiscal Year: 2003
    ..The proposed work will provide a major source of scientific data of relevance to the current debate on ethics of schizophrenia research. ..
  4. TREATMENT OF NEGATIVE SYMPTOMS & COGNITIVE IMPAIRMENTS
    William Carpenter; Fiscal Year: 2003
    ..The study will provide new information on the efficacy of d- cyclosporine and glycine for both persistent primary and secondary negative symptoms and its effect on cognitive functioning. ..